Amikacin in combination with zinc pyrithione prevents growth of a multidrug-resistant carbapenem-resistant Klebsiella pneumoniae isolate

Int J Antimicrob Agents. 2021 Nov;58(5):106442. doi: 10.1016/j.ijantimicag.2021.106442. Epub 2021 Sep 20.

Authors

Jesus Magallon¹, Peter Vu¹, Craig Reeves¹, Stella Kwan¹, Kimberly Phan¹, Crista L Oakley-Havens¹, María Soledad Ramirez¹, Marcelo E Tolmasky²

Affiliations

¹ Center for Applied Biotechnology Studies, Department of Biological Science, California State University Fullerton, Fullerton, CA, USA.
² Center for Applied Biotechnology Studies, Department of Biological Science, California State University Fullerton, Fullerton, CA, USA. Electronic address: [email protected].

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Amikacin / therapeutic use*
Anti-Bacterial Agents / therapeutic use*
Carbapenem-Resistant Enterobacteriaceae / drug effects*
Carbapenem-Resistant Enterobacteriaceae / isolation & purification
Carbapenems / pharmacology
Drug Resistance, Multiple, Bacterial / physiology
Drug Therapy, Combination
Humans
Klebsiella Infections / drug therapy*
Klebsiella pneumoniae / drug effects*
Klebsiella pneumoniae / growth & development
Klebsiella pneumoniae / isolation & purification
Microbial Sensitivity Tests
Organometallic Compounds / therapeutic use*
Pyridines / therapeutic use*

Substances

Anti-Bacterial Agents
Carbapenems
Organometallic Compounds
Pyridines
Amikacin
pyrithione zinc

Grants and funding